Thus, the differential expression of mTOR pathway proteins (PTEN and active forms of AKT and S6) may be possibly predictive markers for tumour response to mTOR inhibition, as described in glioblastoma, prostate and breast cancer cell lines [233,234]. Here, PTEN is linked to neoplasm.